Cargando…

Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review

Previously case reports showed dupilumab may benefit for hand eczema treatment, but relatively comprehensive assessments are lacking. A 45-year-old male with multiple severe vesicles, bullae and pustule on the palmar aspects of both hand and foot diagnosed dyshidrotic eczema by pathology was treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yali, Xiao, Jialing, Sun, Yi, Fang, Hong, Qiao, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830185/
https://www.ncbi.nlm.nih.gov/pubmed/36636704
http://dx.doi.org/10.2147/JAA.S399340
_version_ 1784867618536030208
author Li, Yali
Xiao, Jialing
Sun, Yi
Fang, Hong
Qiao, Jianjun
author_facet Li, Yali
Xiao, Jialing
Sun, Yi
Fang, Hong
Qiao, Jianjun
author_sort Li, Yali
collection PubMed
description Previously case reports showed dupilumab may benefit for hand eczema treatment, but relatively comprehensive assessments are lacking. A 45-year-old male with multiple severe vesicles, bullae and pustule on the palmar aspects of both hand and foot diagnosed dyshidrotic eczema by pathology was treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. The physician’s assessment of the patient revealed an excellent response to the treatment with dupilumab; the lesions and symptoms achieved dramatic improvement on the third day, and at 6 weeks, the hands and feet became completely normal without relapse in the past 1.5 years of discontinuation. Systematic literature searches were performed, and 6 case reports, 5 case series, 2 prospective observational studies and 1 retrospective review with a total of 150 patients were identified to describing the evaluation of efficacy and safety of dupilumab treatment for hand and foot eczema. Dupilumab appears to be safe and well tolerated with clinical benefit in recalcitrant hand and foot eczema. Larger randomized controlled trials using validated outcome measures and detailed hand eczema type and population classification are needed before dupilumab can be applied in clinical settings.
format Online
Article
Text
id pubmed-9830185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98301852023-01-11 Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review Li, Yali Xiao, Jialing Sun, Yi Fang, Hong Qiao, Jianjun J Asthma Allergy Case Report Previously case reports showed dupilumab may benefit for hand eczema treatment, but relatively comprehensive assessments are lacking. A 45-year-old male with multiple severe vesicles, bullae and pustule on the palmar aspects of both hand and foot diagnosed dyshidrotic eczema by pathology was treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. The physician’s assessment of the patient revealed an excellent response to the treatment with dupilumab; the lesions and symptoms achieved dramatic improvement on the third day, and at 6 weeks, the hands and feet became completely normal without relapse in the past 1.5 years of discontinuation. Systematic literature searches were performed, and 6 case reports, 5 case series, 2 prospective observational studies and 1 retrospective review with a total of 150 patients were identified to describing the evaluation of efficacy and safety of dupilumab treatment for hand and foot eczema. Dupilumab appears to be safe and well tolerated with clinical benefit in recalcitrant hand and foot eczema. Larger randomized controlled trials using validated outcome measures and detailed hand eczema type and population classification are needed before dupilumab can be applied in clinical settings. Dove 2023-01-05 /pmc/articles/PMC9830185/ /pubmed/36636704 http://dx.doi.org/10.2147/JAA.S399340 Text en © 2023 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Li, Yali
Xiao, Jialing
Sun, Yi
Fang, Hong
Qiao, Jianjun
Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review
title Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review
title_full Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review
title_fullStr Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review
title_full_unstemmed Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review
title_short Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review
title_sort quick treatment of very severe refractory hand and foot eczema with dupilumab: a case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830185/
https://www.ncbi.nlm.nih.gov/pubmed/36636704
http://dx.doi.org/10.2147/JAA.S399340
work_keys_str_mv AT liyali quicktreatmentofverysevererefractoryhandandfooteczemawithdupilumabacasereportandliteraturereview
AT xiaojialing quicktreatmentofverysevererefractoryhandandfooteczemawithdupilumabacasereportandliteraturereview
AT sunyi quicktreatmentofverysevererefractoryhandandfooteczemawithdupilumabacasereportandliteraturereview
AT fanghong quicktreatmentofverysevererefractoryhandandfooteczemawithdupilumabacasereportandliteraturereview
AT qiaojianjun quicktreatmentofverysevererefractoryhandandfooteczemawithdupilumabacasereportandliteraturereview